CCR5 and breast cancer: MDA-MB-231 and MCF-7 breast cancer cells harbor the intact TGFβ-SMAD pathway; both our results and previous reports showed that CCL5-CCR5 axis could be selectively mediated by pathological or defective forms of TGF-β signaling.